March 31, 2014 Comments Off on Why pharma's 'anti-competitive' practices may actually be good Posted in: General Biotechnology The FTC is reportedly seeking $1 billion from pharmaceutical companies for the role in paying generic companies not to challenge their patents. Despite first appearances, these agreements for a generic company not to challenge a patent, called ‘reverse settlements’, may actually be good for innovation. The rationale for reverse settlements is discussed in my textbook, […]
March 26, 2014 Comments Off on A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape Posted in: General Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape
Go to paperABSTRACT: Patent analytical da…
